Patent classifications
C12P35/06
POLYPEPTIDE HAVING CEPHALOSPORIN C ACYLASE ACTIVITY AND USE THEREOF
Disclosed herein are a polypeptide having cephalosporin C(CPC) acylase activity and a use thereof. More specifically, a mutant CPC acylase comprising a point mutation introduced thereinto, thereby exhibiting improved enzymatic activity and/or stability, and a use of the mutant CPC acylase for producing 7-aminocephalosporanic acid (7-ACA), are provided.
Deacetoxycephalosporin C hydroxylase mutants, DNA encoding the mutants, method for utilizing the mutants and application thereof
This invention provides deacetoxycephalosporin C hydroxylase mutants, their encoding DNA sequences, the methods to utilize them and their application. The deacetoxycephalosporin C hydroxylase mutants are characterized by at least one amino acid mutation at residue position selected from Glycine at position 29, Alanine at position 40, Glycine at position 41, Arginine at position 182 and Threonine at position 272, based on the amino acid sequence shown in SEQ ID NO.:2 as reference sequence, and wherein the deacetoxycephalosporin C hydroxylase mutant has at least 10% increase in activity and at least 150% increase in thermostability compared to wild-type deacetoxycephalosporin C hydroxylase. The deacetoxycephalosporin C hydroxylase mutants in this invention have increased activity and thermostability, allowing them to be more commercially and industrially viable.
Deacetoxycephalosporin C Hydroxylase Mutants, DNA Encoding the Mutants, Method for Utilizing the Mutants and Application Thereof
This invention provides deacetoxycephalosporin C hydroxylase mutants, their encoding DNA sequences, the methods to utilize them and their application. The deacetoxycephalosporin C hydroxylase mutants are characterized by at least one amino acid mutation at residue position selected from Glycine at position 29, Alanine at position 40, Glycine at position 41, Arginine at position 182 and Threonine at position 272, based on the amino acid sequence shown in SEQ ID NO.:2 as reference sequence, and wherein the deacetoxycephalosporin C hydroxylase mutant has at least 10% increase in activity and at least 150% increase in thermostability compared to wild-type deacetoxycephalosporin C hydroxylase. The deacetoxycephalosporin C hydroxylase mutants in this invention have increased activity and thermostability, allowing them to be more commercially and industrially viable.
Xylose isomerase signature sequences
This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.
Xylose isomerase signature sequences
This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.
Xylose isomerases and their uses
This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.
Xylose isomerases and their uses
This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.